Head to Head Analysis: Oncocyte (IMDX) vs. The Competition

Oncocyte (NASDAQ:IMDX) is one of 859 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Oncocyte to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, dividends, risk and profitability.

Institutional & Insider Ownership

55.3% of Oncocyte shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology” companies are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Oncocyte and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9425	14919	44656	1512	2.54

Oncocyte currently has a consensus price target of $10.50, indicating a potential upside of 156.10%. As a group, “Biotechnology” companies have a potential upside of 64.00%. Given Oncocyte’s higher probable upside, equities analysts clearly believe Oncocyte is more favorable than its competitors.

Earnings and Valuation

This table compares Oncocyte and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.75
Oncocyte Competitors	$684.09 million	$8.86 million	-11.37

Oncocyte’s competitors have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Oncocyte and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,423.54%	-126.74%	-33.07%

Risk & Volatility

Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s competitors have a beta of 1.25, meaning that their average stock price is 25% more volatile than the S&P 500.

Summary

Oncocyte beats its competitors on 7 of the 13 factors compared.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.